EE9800234A - Method of treatment and pharmaceutical composition - Google Patents
Method of treatment and pharmaceutical compositionInfo
- Publication number
- EE9800234A EE9800234A EE9800234A EE9800234A EE9800234A EE 9800234 A EE9800234 A EE 9800234A EE 9800234 A EE9800234 A EE 9800234A EE 9800234 A EE9800234 A EE 9800234A EE 9800234 A EE9800234 A EE 9800234A
- Authority
- EE
- Estonia
- Prior art keywords
- treatment
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1132896P | 1996-02-08 | 1996-02-08 | |
| GBGB9608927.1A GB9608927D0 (en) | 1996-04-29 | 1996-04-29 | Method of treatment and pharmaceutical composition |
| PCT/US1997/001799 WO1997028797A1 (en) | 1996-02-08 | 1997-02-04 | Method of treatment and pharmaceutical composion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9800234A true EE9800234A (en) | 1998-12-15 |
Family
ID=26309231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EE9800234A EE9800234A (en) | 1996-02-08 | 1997-02-04 | Method of treatment and pharmaceutical composition |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1014972A4 (en) |
| JP (1) | JPH11504044A (en) |
| KR (1) | KR19990082367A (en) |
| CN (1) | CN1210465A (en) |
| AU (1) | AU732671B2 (en) |
| BG (1) | BG102669A (en) |
| BR (1) | BR9707369A (en) |
| CA (1) | CA2245162A1 (en) |
| CZ (1) | CZ248798A3 (en) |
| EE (1) | EE9800234A (en) |
| IL (1) | IL125446A0 (en) |
| IS (1) | IS4805A (en) |
| NO (1) | NO983641D0 (en) |
| NZ (1) | NZ331160A (en) |
| PL (1) | PL328074A1 (en) |
| SK (1) | SK105698A3 (en) |
| TR (1) | TR199801511T2 (en) |
| WO (1) | WO1997028797A1 (en) |
| YU (1) | YU33298A (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
| US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
| GB9723985D0 (en) | 1997-11-14 | 1998-01-14 | Zeneca Ltd | Pharmaceutical compositions |
| CN1283115A (en) * | 1997-12-23 | 2001-02-07 | 先灵公司 | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US6248308B1 (en) | 1998-04-14 | 2001-06-19 | Sepracor Inc. | Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US6194431B1 (en) * | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| ID29137A (en) * | 1998-07-27 | 2001-08-02 | Schering Corp | HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| PA8481801A1 (en) * | 1998-09-10 | 2000-09-29 | Schering Corp | METHODS AND COMPOSITIONS FOR TREATING SINUSITIS, OTITIS MEDIA AND OTHER RELATED DISORDERS USING ANTIHISTAMINES |
| AU3924500A (en) * | 1999-03-29 | 2000-10-16 | Schering Corporation | Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine |
| DE10007203A1 (en) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist |
| AU2002227240A1 (en) * | 2000-10-30 | 2002-05-15 | Schering Corporation | Treatment and method using loratadine and montelukast |
| US20020198228A1 (en) * | 2001-04-03 | 2002-12-26 | Kaura Sita R. | Composition and method for the treatment of respiratory desease |
| MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| WO2004087095A2 (en) * | 2003-03-31 | 2004-10-14 | Osmotica Costa Rica, Sociedad Anonima | Osmotic controlled release device containing zafirlukast and an h1-antagonist |
| EP1680084A2 (en) * | 2003-10-21 | 2006-07-19 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
| WO2005089748A1 (en) * | 2004-03-17 | 2005-09-29 | Pfizer Limited | Combination for treating inflammatory diseases |
| MX2007004976A (en) | 2004-10-25 | 2007-06-14 | Schering Corp | M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders. |
| TR200806298A2 (en) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulation |
| TW201111392A (en) | 2009-06-16 | 2011-04-01 | Schering Corp | Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof |
| KR101540191B1 (en) * | 2014-02-24 | 2015-07-28 | 성균관대학교산학협력단 | Composition comprising Loratadine for anti-inflammation |
| KR20210114962A (en) * | 2019-01-10 | 2021-09-24 | 장인 무코케어 파마슈티컬 컴퍼니 리미티드 | New formulations containing leukotriene receptor antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5270324A (en) * | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5472964A (en) * | 1992-12-22 | 1995-12-05 | Merck Frosst Canada, Inc. | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
-
1997
- 1997-02-04 KR KR1019980706097A patent/KR19990082367A/en not_active Withdrawn
- 1997-02-04 NZ NZ331160A patent/NZ331160A/en unknown
- 1997-02-04 CN CN97192149A patent/CN1210465A/en active Pending
- 1997-02-04 SK SK1056-98A patent/SK105698A3/en unknown
- 1997-02-04 WO PCT/US1997/001799 patent/WO1997028797A1/en not_active Ceased
- 1997-02-04 BR BR9707369A patent/BR9707369A/en not_active Application Discontinuation
- 1997-02-04 PL PL97328074A patent/PL328074A1/en unknown
- 1997-02-04 CZ CZ982487A patent/CZ248798A3/en unknown
- 1997-02-04 IL IL12544697A patent/IL125446A0/en unknown
- 1997-02-04 CA CA002245162A patent/CA2245162A1/en not_active Abandoned
- 1997-02-04 AU AU22579/97A patent/AU732671B2/en not_active Ceased
- 1997-02-04 TR TR1998/01511T patent/TR199801511T2/en unknown
- 1997-02-04 EP EP97905757A patent/EP1014972A4/en not_active Withdrawn
- 1997-02-04 JP JP9528627A patent/JPH11504044A/en active Pending
- 1997-02-04 EE EE9800234A patent/EE9800234A/en unknown
-
1998
- 1998-07-22 IS IS4805A patent/IS4805A/en unknown
- 1998-08-05 BG BG102669A patent/BG102669A/en unknown
- 1998-08-06 YU YU33298A patent/YU33298A/en unknown
- 1998-08-07 NO NO983641A patent/NO983641D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK105698A3 (en) | 1999-05-07 |
| AU2257997A (en) | 1997-08-28 |
| AU732671B2 (en) | 2001-04-26 |
| EP1014972A1 (en) | 2000-07-05 |
| PL328074A1 (en) | 1999-01-04 |
| EP1014972A4 (en) | 2004-12-08 |
| KR19990082367A (en) | 1999-11-25 |
| BR9707369A (en) | 1999-07-20 |
| CA2245162A1 (en) | 1997-08-14 |
| YU33298A (en) | 1999-11-22 |
| CN1210465A (en) | 1999-03-10 |
| CZ248798A3 (en) | 1999-01-13 |
| WO1997028797A1 (en) | 1997-08-14 |
| BG102669A (en) | 1999-04-30 |
| NO983641L (en) | 1998-08-07 |
| JPH11504044A (en) | 1999-04-06 |
| NZ331160A (en) | 2000-07-28 |
| IL125446A0 (en) | 1999-03-12 |
| NO983641D0 (en) | 1998-08-07 |
| TR199801511T2 (en) | 1998-10-21 |
| IS4805A (en) | 1998-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9407799A (en) | Composition of matter treatment method and pharmaceutical composition | |
| EE9800234A (en) | Method of treatment and pharmaceutical composition | |
| FI971969A0 (en) | Compositions and method of use for the treatment of hemorrhoids | |
| FI964028L (en) | New pharmaceutical formulation and method | |
| FI973163L (en) | Treatment of incontinence using (S)-oxybutynin and (S)-desethyloxybutynin | |
| EE03976B1 (en) | Erythromycins and method of their preparation | |
| BR9504072A (en) | Pharmaceutical composition methods for the treatment of atherosclerosis hypercholesterolemia and kit | |
| DE69831755D1 (en) | OPTOACUSTIC CONSTANCES AND METHOD OF USE | |
| EE03966B1 (en) | Compounds with analgesic activity and method of their preparation | |
| BR9604959A (en) | Composition and method for the treatment of tooth desensitization | |
| AUPO727097A0 (en) | Method of treatment of hepatoma and pharmaceutical compositions for use therein | |
| FI971349L (en) | Asphalt remover and method of use | |
| FI971750A0 (en) | Compositions for the treatment of multiple sclerosis and its treatment | |
| FI951060L (en) | Formulations and treatment methods | |
| EE200000226A (en) | 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition | |
| FI915287A7 (en) | Wastewater treatment method and composition | |
| FI972235L (en) | Method for using triarylethylene derivatives in the treatment and prevention of osteoporosis | |
| UA10998C2 (en) | METHOD OF POLYFACTORY THERAPEUTIC ACTION AND BLANKET FOR POLYFACTORY THERAPEUTIC ACTION | |
| FI952297L (en) | Fluoride-releasing dental primer composition and method of using the same | |
| EE9800164A (en) | Pharmaceutical composition and method for treating epithelioma | |
| BR9710544A (en) | Composite treatment method and pharmaceutical composition | |
| FI933642A7 (en) | Composition and methods for forming bone | |
| FI953260A7 (en) | Pharmaceutical compositions and method for their preparation | |
| DE69524527D1 (en) | AIDS-inhibiting drug preparation and method | |
| EP1009433A4 (en) | Therapeutic composition and method of treatment |